Abstract
At present, there is no standard of care on the use of letrozole in ovarian cancer management. We performed a systematic review of the available literature addressing this issue. Data demonstrated a role for letrozole in ovarian cancer, in both the primary and recurrent setting. Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials.
Lingua originale | English |
---|---|
pagine (da-a) | 1058-1064 |
Numero di pagine | 7 |
Rivista | International Journal of Gynecological Cancer |
Volume | 30 |
DOI | |
Stato di pubblicazione | Pubblicato - 2020 |
Keywords
- medical oncology
- ovarian cancer